nach oben

Erschienen in:

01.03.2010 | Reproductive Medicine

Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients

verfasst von: Levent Kebapcilar, Oktay Bilgir, Cuneyt Eftal Taner, Ayse Gul Kebapcilar, Didem L. Kozaci, Ahmet Alacacioglu, Yasar Yildiz, Arif Yuksel, Ismail Sari

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients.

Methods

Fifty-six women with PCOS were randomized into two treatment protocols: ethinylestradiol + cyproterone acetate (2 mg, EE/CA; n = 28), and EE/CA with spironolactone (Sp; n = 28). Plasma sCD40L levels were measured before and after a 3-month treatment.

Results

Before the initiation of treatment, the sCD40L levels were not significantly different between the groups [EE/CA (1.33 ng/mL) vs. EE/CA + Sp (1.23 ng/mL); P > 0.05]. In the post-treatment period, sCD40L concentrations were increased compared with pre-treatment values in the EE/CA and EE/CA + Sp groups (1.33 vs. 2.70 ng/mL, P = 0.011; and 1.23 vs. 2.41 ng/mL, P = 0.017; respectively).

Conclusion

Increased plasma concentrations of sCD40L are associated with OCP and OCP + Sp treatment regimens in PCOS patients.

Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861CrossRefPubMed

Doring A, Frohlich M, Lowel H, Koenig W (2004) Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 172:281–286CrossRefPubMed

Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527–1535CrossRefPubMed

Karakurt F, Gumus II, Bavbek N, Kargili A, Koca C, Selcoki Y, Ozbek M, Kosar A, Akcay A (2008) Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 24:491–497CrossRefPubMed

Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2009) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280:187–193CrossRefPubMed

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

Yalcin AI, Dincer M, Aslan V, Gulbas Z (2002) Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 25:260–264CrossRefPubMed

Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ (2003) Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88:3867–3873CrossRefPubMed

Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137 Suppl:S89–S95CrossRefPubMed

10.

André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899CrossRefPubMed

11.

Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB (2009) Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 91:2545–2550CrossRefPubMed

12.

Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268CrossRefPubMed

13.

Geraldes P, Gagnon S, Hadjadj S, Merhi Y, Sirois MG, Cloutier I, Tanguay JF (2006) Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ER alpha-mediated pathway. Cardiovasc Res 71:566–573CrossRefPubMed

14.

Lahita RG (2000) Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 26:951–968CrossRefPubMed

15.

Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI (2001) Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 28:2644–2649PubMed

16.

Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797PubMed

17.

Stice JP, Knowlton AA (2008) Estrogen, NFkappaB, and the heat shock response. Mol Med 14:517–527CrossRefPubMed

18.

Tsytsykova AV, Tsitsikov EN, Geha RS (1996) The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 271:3763–3770CrossRefPubMed

19.

Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M (2002) Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520–525CrossRefPubMed

Titel: Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients
verfasst von: Levent Kebapcilar
Oktay Bilgir
Cuneyt Eftal Taner
Ayse Gul Kebapcilar
Didem L. Kozaci
Ahmet Alacacioglu
Yasar Yildiz
Arif Yuksel
Ismail Sari
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-1189-7

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients